Peptide record

TPDB09846

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09846
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 iACP-DRLF AFP-GFuse Antifungipept CAFPdb i2APP APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 21-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLPKMSTKLRVPYRRGTKDYH
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C118H189N35O29S1
ANCEQIW
RK
2594.08
10.94
7
1
7
+5
3.02
-1.133
50.95
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
2980
1.15
5
Residue Composition
number
0
A
3
R
0
N
1
D
0
C
0
E
0
Q
1
G
1
H
0
I
2
L
3
K
1
M
1
F
2
P
1
S
2
T
0
W
2
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 0 L: 2 K: 3 M: 1 F: 1 P: 2 S: 1 T: 2 W: 0 Y: 2 V: 1
Chemical Descriptors
21 reviewed residue count
C118H189N35O29S1 sequence-only estimate (linear, free termini)
2594.08 sequence-only estimate (linear, free termini)
10.94 sequence-only estimate (linear, free termini)
+5 sequence-only estimate (linear, free termini)
3.02 sequence-only estimate (linear, free termini)
-1.133 sequence-only estimate (linear, free termini)
Evidence Records 17 records
Evidence 1 Activity

Activity

MIC
Antibacterial
12.5 ug/mL

Target

Escherichia coli ATCC25629

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC
Evidence 2 Activity

Activity

MIC
Antibacterial
1.2 ug/mL

Target

Staphylococcus aureus ATCC2576

Source & Reference

dbAMP DRAMP

Other

Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and
Evidence 3 Activity

Activity

MIC
Antibacterial
15 ug/mL

Target

Candida albicans ATCC 300

Source & Reference

dbAMP DRAMP

Other

, resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and C. albicans ATCC 300 (MIC 15 ug/mL). it caused 46.3% histamine release from mast cells at 100 ug/ml.
Evidence 4 Activity

Activity

MIC
Antifungal
12.5 ug/mL

Target

Escherichia coli ATCC25629

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC
Evidence 5 Activity

Activity

MIC
Antifungal
1.2 ug/mL

Target

Staphylococcus aureus ATCC2576

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and
Evidence 6 Activity

Activity

MIC
Antifungal
15 ug/mL

Target

Candida albicans ATCC 300

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

, resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and C. albicans ATCC 300 (MIC 15 ug/mL). it caused 46.3% histamine release from mast cells at 100 ug/ml.
Evidence 7 Activity

Activity

MIC
Antiparasitic
12.5 ug/mL

Target

Escherichia coli ATCC25629

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC
Evidence 8 Activity

Activity

MIC
Antiparasitic
1.2 ug/mL

Target

Staphylococcus aureus ATCC2576

Source & Reference

DRAMP

Other

Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and
Evidence 9 Activity

Activity

MIC
Antiparasitic
15 ug/mL

Target

Candida albicans ATCC 300

Source & Reference

DRAMP

Other

, resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and C. albicans ATCC 300 (MIC 15 ug/mL). it caused 46.3% histamine release from mast cells at 100 ug/ml.
Evidence 10 Activity

Activity

MIC
Antiviral
12.5 ug/mL

Target

Escherichia coli ATCC25629

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC
Evidence 11 Activity

Activity

MIC
Antiviral
1.2 ug/mL

Target

Staphylococcus aureus ATCC2576

Source & Reference

DRAMP

Other

Active against E. coli ATCC25629 (MIC 12.5 ug/mL), resistant E. coli (MIC 15), S. aureus ATCC2576 (MIC 1.2 ug/mL), resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and
Evidence 12 Activity

Activity

MIC
Antiviral
15 ug/mL

Target

Candida albicans ATCC 300

Source & Reference

DRAMP

Other

, resistant S. aureus (MIC 5), normal ATCC293 and resistant B. dysenteriae (MIC 7.5), and C. albicans ATCC 300 (MIC 15 ug/mL). it caused 46.3% histamine release from mast cells at 100 ug/ml.
Evidence 13 Activity

Activity

% Hemolysis
Hemolysis
2 %
[Ref.19716842]25 ± 2% hemolytic activity at 50 µg/ml against human red blood cells

Target

human red blood cells

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Toxicon. 2010 Feb-Mar 55(2-3):274-279.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 14 Activity

Activity

25% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
25% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Two novel antimicrobial peptides from centipede venoms. | Toxicon | 2010
Evidence 15 Activity

Activity

21% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
21% Hemolysis | 50 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Two novel antimicrobial peptides from centipede venoms. | Toxicon | 2010
Evidence 16 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref.19716842]25 ± 2% hemolytic activity at 50 µg/ml against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Toxicon. 2010 Feb-Mar 55(2-3):274-279.
Evidence 17 Hemolysis

Activity

2 %
% Hemolysis
[Ref.19716842]25 ± 2% hemolytic activity at 50 µg/ml against human red blood cells
Hemolysis

Target

human red blood cells

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Toxicon. 2010 Feb-Mar 55(2-3):274-279.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.